Form 4: Niagen Bioscience Director Kristin Patrick Acquires 20,000 Stock Options

Kristin Patrick, a Director at Niagen Bioscience, Inc., has acquired 20,000 stock options with an exercise price of $14.13, vesting fully on June 24, 2026.

Summary

• Kristin Patrick, a Director of Niagen Bioscience, Inc. (NAGE), acquired 20,000 stock options on June 24, 2025.
• The stock options have an exercise price of $14.13 per share.
• These options will vest 100% on June 24, 2026.
• The expiration date for these options is June 23, 2035.
• Following this transaction, Kristin Patrick beneficially owns 20,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director is generally viewed as a positive sign of alignment between management and shareholder interests, as it incentivizes long-term performance. However, it is a routine compensation event and not indicative of significant operational news.

Positives

• The acquisition of stock options by a director aligns their interests with those of shareholders, as the options gain value if the company's stock price increases.
• The grant of options as compensation is a common practice to incentivize long-term performance and retention of key personnel.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is solely a report of an insider transaction.

Industry Context

The grant of stock options to directors is a standard practice across various industries, including biotechnology, as a form of equity compensation designed to align the interests of management with those of shareholders. This specific filing reflects a routine compensation event for a director at Niagen Bioscience, Inc.

Related Party Transactions

• The grant of stock options to Kristin Patrick, a director, constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options can be seen as a positive for shareholders as it aligns the director's financial interests with the company's stock performance.
• Director (Kristin Patrick): This transaction represents a component of her compensation package, providing a long-term incentive tied to the company's success.

Next Steps

• The stock options will vest 100% on June 24, 2026, at which point Kristin Patrick will be able to exercise them.

Key Dates

Keywords

Niagen Bioscience, NAGE, Kristin Patrick, Stock Option, Director, SEC Form 4, Insider Transaction, Equity Compensation